Table 1.
Baseline characteristics and laboratory findings of patient and control groups.
| Control (n=33) | Patient (n=57) | P value | |
|---|---|---|---|
| Age (years) | 55±7 | 57±8 | 0.205 |
| Gender (Male) | 12 (36) | 24 (42) | 0.592 |
| Hypertension | 19 (58) | 43 (74) | 0.115 |
| Diabetes | 8 (24) | 16 (28) | 0.692 |
| Coronary artery disease | 6 (18) | 20 (35) | 0.088 |
| Smoking | 7 (21) | 11 (19) | 0.827 |
| RAS blockers | 11 (33) | 30 (53) | 0.076 |
| β-blockers | 7 (21) | 20 (35) | 0.166 |
| Calcium channel blockers | 7 (21) | 9 (16) | 0.517 |
| Statins | 6 (18) | 15 (26) | 0.379 |
| Acetyl salicylic acid | 11 (33) | 24 (42) | 0.411 |
| Body mass index (kg/m2) | 30.3±4.3 | 31.3±4.2 | 0.281 |
| Systolic blood pressure (mmHg) | 132±23 | 139±21 | 0.173 |
| Diastolic blood pressure (mmHg) | 80 [70–90] | 85 [80–90] | 0.530 |
| Glucose (mg/dL) | 99 [92–110] | 105 [93–127] | 0.132 |
| Thyroid stimulating hormone (μIU/mL) | 1.30 [0.85–1.70] | 1.20 [0.8–1.85] | 0.834 |
| Creatinine (mg/dL) | 0.7 [0.6–0.9] | 0.8 [0.6–0.9] | 0.990 |
| Ceatinine clearance (mL/min/1.73 m2) | 114±28 | 115±36 | 0.906 |
| Cholesterol (mg/dL) | 196±42 | 196±42 | 0.961 |
| Triglyceride (mg/dL) | 161±89 | 153±61 | 0.614 |
| LDL-cholesterol (mg/dL) | 127±36 | 125±40 | 0.979 |
| HDL-cholesterol (mg/dL) | 45±11 | 46±13 | 0.493 |
| Hemoglobin (gr/dL) | 13.7±1.6 | 13.4±1.6 | 0.475 |
| CT-1 (fmol/mL) | 11.30 [8.09–16.51] | 17.5 [8.95–28.74] | 0.002* |
| NT-proBNP (pg/mL) | 64 [27.5–95] | 82 [55.5–241] | 0.007* |
RAS – Renin-angiotensin system; LDL – Low-density lipoprotein; HDL – High-density lipoprotein; CT-1 – Cardiotrophin-1; NT-proBNP – N terminal pro B-type natriuretic peptide. Data are shown as n (%), mean ± SD, median [interquartile range].
*
calculated by log transformed data.